Mechanism of Action
Insulin Receptor Tyrosine Kinase
Insulin binds the insulin receptor (IR), a heterotetrameric transmembrane tyrosine kinase. Ligand binding triggers auto-phosphorylation of the receptor's cytoplasmic beta-subunits, recruiting IRS-1/2 scaffold proteins. IRS phosphorylation activates two major downstream cascades: PI3K/Akt/PKB (mediating GLUT4 translocation, glycogen synthesis, protein synthesis, and anti-apoptotic signaling) and Ras/MAPK/ERK (mediating cell proliferation and gene transcription).
Glucose Uptake and Metabolic Effects
Akt activation phosphorylates AS160 (TBC1D4), releasing GLUT4 vesicles from intracellular storage to fuse with the plasma membrane of muscle and adipose cells, increasing glucose uptake 10-20-fold. In the liver, insulin suppresses gluconeogenesis by phosphorylating and inactivating FOXO1 and activates glycogen synthase. In adipose tissue, insulin inhibits hormone-sensitive lipase, preventing lipolysis and reducing free fatty acid release.
Research Summary
Diabetes Management
HumanInsulin remains the gold-standard therapy for type 1 diabetes and is required by many type 2 patients. The DCCT trial established tight glycemic control with intensive insulin therapy reduces microvascular complications by 60-76%. Modern insulin analogs (glargine, detemir, degludec for basal; lispro, aspart, glulisine for rapid-acting) have dramatically improved glycemic control and quality of life. Closed-loop artificial pancreas systems combining CGM with insulin pump are now commercially available.
Performance Enhancement (Abuse Concern)
HumanInsulin is WADA-prohibited for non-diabetic athletes due to its anabolic properties: promoting amino acid uptake, glycogen synthesis, and anti-catabolic effects on muscle. Supraphysiological insulin doses are acutely dangerous (severe hypoglycemia, coma, death) and represent one of the highest-risk performance-enhancing drug abuses. Therapeutic use exemptions are granted for diabetic athletes.
Intranasal Insulin for CNS Effects
HumanIntranasal insulin delivery bypasses peripheral metabolism and accesses CNS insulin receptors directly. Phase II trials demonstrated intranasal insulin improved memory and executive function in Alzheimer's disease and mild cognitive impairment without systemic hypoglycemia. Insulin resistance in the brain is now considered a contributor to Alzheimer's pathology, and insulin sensitization is an emerging therapeutic target.
Calculate your Insulin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| T1D glucose management | Individualized (0.5-1 U/kg/day) | Multiple daily injections or pump | Subcutaneous |
| Cognitive / CNS research | 20-40 IU | Single intranasal dose or daily x weeks | Intranasal |
| Hyperinsulinemic clamp (research) | 1-2 mU/kg/min | Continuous research infusion | Intravenous |
Therapeutic insulin dosing requires individualization and glucose monitoring. Non-diabetic use of insulin for performance enhancement is medically dangerous and WADA-prohibited.
Interactions
Safety Profile
Insulin is one of the safest drugs when correctly dosed in people with insulin deficiency. Hypoglycemia is the primary safety concern, mild hypoglycemia causes symptoms; severe hypoglycemia can cause seizures, brain damage, or death. Lipohypertrophy at injection sites from repeated injections impairs absorption. Allergic reactions are rare with modern recombinant human insulin. In non-diabetic individuals, exogenous insulin is extremely dangerous due to hypoglycemia risk.
References
- [1]Banting FG, et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12(3):141-146.
- [2]DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications. N Engl J Med. 1993;329(14):977-986.
- [3]Craft S, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol. 2012;69(1):29-38.